Venlafaxine-Associated Hypomania in Unipolar Depression
Dear Editor: Antidepressant-induced hypomania and mania have been reported more commonly in cases of bipolar depression than in cases of unipolar depression (1) . Tricyclic antidepressants, monoamine oxidase inhibitors, and even selective serotonin reuptake inhibitors have been associated with this switch (1) . Newer antidepressants like venlafaxine, which act on multiple specific receptors, have low propensity for the switch (2) but are not completely safe, particularly in patients with bipolar depression or with family history of bipolarity (3) (4) (5) . The following case report illustrates that venlafaxine may also be associated with a switch to hypomania in unipolar depression.
Case Report
Mr S, aged 26 years and single, presented to our clinic with a 2-year history of sustained sadness of mood, withdrawal, decreased interest in enjoyable activities, increased tiredness, ideas of hopelessness and worthlessness, past attempted suicide, death wish, and decreased sleep and appetite. One year earlier, he had undergone treatment including electroconvulsive therapy (twice) from a private psychiatrist but did not perceive significant benefit. He had been off medication for the 6 months prior to presentation. Two years earlier, his elder brother had committed suicide at age 30 years, following an altercation with family members. Apart from this, there was no personal or family history of affective illness, panic disorder, obsessive-compulsive disorder, substance use, or psychosis. No delusions or hallucinations were forthcoming, either at the time of assessment or historically. Results of a general physical examination and laboratory investigation, including a thyroid function test, were normal. He was diagnosed with severe depression without psychotic symptoms, and treatment with venlafaxine 75 mg daily, together with clonazepam 0.5 mg daily to promote sleep, was started. In the next 3 weeks, he reported 50% improvement in overall symptoms. At the end of week 3, venlafaxine was increased to 112.5 mg daily to enhance his improvement.
At the end of 5 weeks of total treatment, he was noticed to have decreased sleep, overactivity, overtalkativeness, and excessive cheerfulness. He was cracking jokes, voicing grandiose ideas, spending excessively, and smoking more. During interview, he subjectively complained of racing thoughts and new ideas. He himself had discontinued his increased medication after 2 weeks because he felt well. His symptoms continued until his family members brought him to hospital. Drug-induced hypomanic switch was considered, and lithium carbonate was started, along with benzodiazepine. At the end of 4 weeks, he became asymptomatic.
The patient developed possible venlafaxineinduced switch within 8 weeks of starting the medication (6) , and the symptoms continued, although they did not worsen, even after he stopped taking the drug. The presence of predisposing factors for bipolarity (7) , that is, early age of onset, long duration of a depressive episode, and a family history of suicide, probably made this patient vulnerable to a switch to hypomania on taking therapeutic dosages of venlafaxine, as shown by similar cases in the literature (3) . It is important to acknowledge that it is difficult to prove a causal connection between the introduction of venlafaxine and onset of hypomania, but venlafaxine possibly exposed latent bipolarity in this patient, which led to rapid institution of a mood stabilizer to prevent further morbidity.
Prior to starting any antidepressant, clinicians should attempt to obtain risk factors for bipolarity (that is, cyclothymic or hyperthymic temperament, early onset of depression, acute onset, atypical symptoms, seasonal pattern, and family history of bipolar disorder) to help in early detection and intervention when a manic or hypomanic switch occurs.
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Hypnopompic Hallucinations During Olanzapine Treatment
Deear Editor: A young man, aged 22 years, was taken for a psychiatric consultation after he had expressed death threats toward his cousin. From the information supplied, it was deduced that he had dramatically reduced his social contacts over the past 3 years and had given up all the activities that he previously enjoyed. After the consultation, we were able to draw a clinical picture that was characterized by indifference, bizarre behaviour, serious relational difficulties, and withdrawal from activities and interests. Judging from the current symptomology and from the clinical history, we diagnosed schizophrenia. As the main symptoms were negative, we decided to prescribe olanzapine. The starting dosage was 5 mg daily, gradually increased to 20 mg daily over a 1-month period. Our patient had never taken any psychotropic drug. Apart from the disappearance of paranoid symptoms (which had manifested themselves as death threats toward his cousin) a few days after the patient reached the olanzapine dosage of 20 mg daily, we also noticed improvement in the bizarre behaviour that had affected some of his daily activities. His social contacts also improved significantly. However, the therapy made the patient complain of a persistent sedative state and, strangely enough, he reported that upon waking he saw large spiders walking across the ceiling. Having noticed great therapeutic results despite the patient's complaints of sedative effects, and because he did not complain about the hypnopompic hallucinations, we continued olanzapine therapy for about 2 more months. The patient then started to complain more vociferously about sedation and continued to refer to the visual hallucinations mentioned above, which he had previously tolerated. Because these symptoms were totally discordant with the clinical picture drawn before treatment, we decreased the dosage from 20 to 15 mg, and then to 10 mg daily, over a 1-month period. Both sedation and hypnopompic hallucinations persisted at 10 mg daily, but above all, the clinical picture worsened, particularly with regard to social withdrawal. We therefore decided to discontinue olanzapine and replace it with risperidone.
We believe that olanzapine induced the hypnopompic hallucinations claimed by the patient. With regard to olanzapine's side effects, the drug literature has never reported imperceptive symptoms such as hypnopompic hallucinations. Conversely, cases of hypnopompic hallucinations have been reported during therapy with imipramine, amitriptyline, maprotiline, and donezepil. Schlauch has reported a case of hypnopompic hallucinations during therapy with imipramine and has suggested that such hallucinations may be connected to the decrease in rapid eye movement (REM) sleep caused by imipramine (1). Hemmingsen and Rafaelsen reported 4 cases of hypnopompic and hypnagogic hallucinations during therapy with amitriptyline (2) . According to these authors, there is a connection between amitriptyline effects on the brain, sleep patterns, and clinical condition. In our case, hallucinations appeared after a few days of treatment with olanzapine and continued for approximately 2 more months, manifesting themselves every morning as the patient woke up. The patient had never previously suffered hallucinations. They disappeared after the discontinuation of olanzapine therapy and did not reappear when another antipsychotic was administered.
The discontinuation of therapy was not determined by the hallucinations, which our patient tolerated, but by sedative side effects. Olanzapine at a dosage of 5 mg daily significantly increases slow wave sleep, probably by blocking 5-HT 2C receptors; it improves the continuity of sleep and the subjective quality of sleep. At a dosage of 10 mg, olanzapine significantly increases the latency of REM sleep and also decreases its duration. Such effects may be a consequence of the antagonist effects of olanzapine at muscarinic cholinergic receptors (3) . Inhibition of REM sleep, as we have mentioned above, is a common property of tricyclics.The manifestation of hypnopompic hallucinations caused by olanzapine could be similar to that described for tricyclics and is therefore probably linked to REM-sleep suppression.
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Atypical Neuroleptic Malignant Syndrome Caused by Clozapine and Venlafaxine: Early Brief Treatment With Dantrolene
Dear Editor: Clozapine can cause neuroleptic malignant syndrome (NMS) with a presentation that may be atypical in that it may occur without rigidity, fever, or changes in creatine kinase (CK) (1). We report a case of possible atypical NMS arising from overdosage of clozapine and venlafaxine that was successfully treated with lorazepam and dantrolene.
Case Report
Mr A, aged 19 years, was diagnosed with shizoaffective disorder. Treatment for 2 years with clozapine 300 mg daily and venlafaxine 150 mg daily helped his condition. After he discontinued his medication for 2 weeks and then took 1000 mg clozapine and 900 mg venlafaxine, he presented to the emergency room, where he went into a coma and was admitted to the intensive care unit. His urine was positive for cannabinoids and clozapine but negative for alcohol, opiates, amphetamines, cocaine, and benzodiazepines. His temperature was 37.2EC.
The following day he emerged from coma and developed delirium, agitation, fluctuating blood pressure, a temperature of 38EC, and leukocytosis. He was without extrapyramidal signs (EPS) and had normal CK. Intravenous lorazepam 12 mg daily was added to his treatment. At day 3, his CK rose to 6700 U/L, and his myoglobin rose to 597 ng/L. Suspecting NMS, we added dantrolene 1 mg/kg 4 times daily. Twelve hours later, the patient's CK decreased to 3600 U/L. Glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT) rose to 147 U/L and 91 U/L, respectively. After 3 more days, the patient's CK level was 1750 U/L, his temperature and myoglobin became normal, EPS were absent, consciousness was total, and paranoid delusion and depression emerged. Dantrolene was discontinued, and the patient was transferred to the psychiatric unit.
Ten days later, all parameters were normalized, especially CK, myoglobin, white blood cell count, GOT, and GPT.
After 10 more days, risperidone 2 mg daily was added and titrated to 3 mg daily. The patient improved and was discharged; 60 days later, he was in good clinical condition.
This patient presented NMS that was atypical in that muscular rigidity was absent during the periods with fever, (common with clozapine-related NMS), high CK, altered consciousness and autonomic dysregulation.
NMS occuring after a single dose of venlafaxine has been attributed to a dopamineinhibiting effect (2) or, alternatively, it has been explained as evidence of central serotonergic overdrive (3) . NMS and serotonin syndrome (SS) are often confused, and when considering their clinical overlap, many authors place NMS and SS in the spectrum of the same disorder (4), defined by some as "neurotoxic syndrome" (5) and also including catatony (6) .
Dantrolene's specificity of action remains unknown (7) ; however, in the case of our patient, adding dantrolene to lorazepam was crucial, even in the absence of rigidity. Early treatment with dantrolene prevented NMS from developing fully. Otherwise, the absence of rigidity is unrelated to this treatment, a characteristic of some NMS with better prognosis.
Fever, altered consciousness, and increased CK and myoglobin indicated treatment with dantrolene.
